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Introduction 16
The efficient regulation of neuroendocrine stress systems including the hypothalamic-pituitary-adrenal 17 (HPA) axis is relevant not only with regard to their activation in response to environmental challenges, 18 but also to endogenous circadian rhythms. Release of adrenocorticotropin (ACTH) and cortisol is 19 triggered by corticotropin-releasing hormone (CRH) and regulated via glucocorticoid feedback at the 20 hippocampal and hypothalamic levels. In the first night-half, ACTH and cortisol concentrations reach 21 nadir values which indicate basal secretory HPA axis activity in the absence of external stimulation 22 (Kern et al., 1996) . Elderly humans display changes in sleep-related neuroendocrine patterns, in 23 particular a decrease in growth hormone release and an increase in HPA axis activity, which are 24 paralleled by a reduction in the amount of time spent in rapid eye-movement (REM) and slow-wave insulin on ACTH and cortisol secretion particularly in elderly subjects. 37
Materials and Methods 38
Participants 39
Fourteen healthy elderly volunteers (8 men, 6 women; age, mean ± SEM, 70.00 ± 0. respectively, Experiments I and II. In the young participants, sleep-related electroencephalographicM A N U S C R I P T
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4 power spectra and memory performance were analyzed in addition and have been reported elsewhere 44 (Feld et al., 2016) . Relevant illness of our subjects was excluded by medical history and clinical 45 examination. All subjects reported having a regular sleep-wake cycle and were not on medication 46 except for estrogen-dominant oral contraceptives taken by all young women. All subjects spent one 47 night in the sleep laboratory to adapt to the experimental procedure; visual inspection of respective 48 polysomnographical results ensured that none of the subjects displayed highly abnormal sleep 49 characteristics. They gave written informed consent to the study that conformed to the Declaration of 50
Helsinki and was approved by the local ethics committee. 51
Study design and procedure 52
Experiments followed a balanced, placebo-controlled, double-blind, within-subject, crossover design. 53
All participants took part in two sessions which were identical except for the administration of insulin 54 or placebo. Sessions were scheduled to be apart as close to 28 days as possible and the young women 55 did not participate during their menstruation phases. Subjects were told to get up around 0700 h and to 56 abstain from naps or caffeine intake on experimental days, and to follow their usual dinner routines 57 around 1800-1900 h. Experiments started around 2000 h. Electrodes were attached for standard 58 polysomnographic recordings including electroencephalogram (at sites C3 and C4) that were scored 59 offline according to standard criteria as wake, sleep stages N1, N2, N3, and REM sleep. At 2230 h, 60 subjects were intranasally administered a total dose of 1.6 ml insulin (160 IU; Insulin Actrapid; Novo 61
Nordisk, Mainz, Germany) or vehicle (carrier solution) via sixteen 0.1 ml puffs (8 per each nostril) in 62 1-min intervals. Subjects were allowed to sleep between 2300 h (lights off) and 0700 h (awakening), 63 which corresponded to the period of polysomnographical recordings. 64
Blood sampling and control measures 65
Peripheral blood for the assessment of serum cortisol, C-peptide, insulin, as well as glucose and 66 plasma ACTH was sampled during a pre-sleep baseline and at 20-to 40-min intervals during the first 67 night-half until 0320 h (see Figure 1 ). For the group of elderly subjects, slight adjustments in the blood 68 sampling schedule were introduced in order to increase the feasibility of repeated blood sampling and 69 to restrict the burden of experimental participation, resulting in minor respective differences to theM A N U S C R I P T
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group of young subjects outside the main time period of interest (2300-0020 h). Blood was drawn via 71 long thin tubes enabling blood collection from an adjacent room while minimizing disruptive effects 72 on the subject's sleep. Routine assays were used to determine concentrations of ACTH, cortisol, C-73 peptide (all Immulite, DPC, Los Angeles, CA), insulin (Insulin ELISA Kit, Dako, Glostrup, 74 Denmark), and glucose (HemoCue Glucose 201 Analyzer, HemoCue AB, Ångelholm, Sweden). 75
Appetite, thirst, and sleepiness were self-reported on visual analogue scales (0-100 mm) in 76 both experiments. Mood, well-being and subjective sleep quality were assessed via established rating 77 scales, and heart rate and blood pressure were monitored before and after sleep. 78
Statistical analyses 79
For analysis of sleep stages, one female and one male participant of Experiment II were excluded 80 because of data loss. Analyses relied on Greenhouse-Geisser-corrected analyses of covariance 81 (ANCOVA) for repeated measurements with baseline values as covariates and the between subject-82 factor 'sex' (male/female) and the within-subject factors 'treatment' (insulin/placebo) and 'time'. 83
Areas under the curve (AUC) calculated according to the trapezoidal rule and single time points were 84 compared by t-tests. For comparisons between elderly and young subjects, linear mixed models were 85 used with the between-subject factor age (elderly/young). In addition, individual slope coefficients 86 were obtained in the form of beta weights of linear regression lines fitted to ACTH and cortisol values 87 between 2300-0320 h, and were compared between groups by two-tailed unpaired t-tests. A P-value 88 < 0.05 was considered significant; data are presented as means ± SEM. 89 90
Results 91
Increased HPA axis activity during early sleep in elderly compared to young subjects 92
Cortisol AUC 2300-0320 h values were higher in elderly compared to young subjects (13,472 ± 584 vs. placebo conditions were moderately correlated with BMI in the elderly (r = 0.54, P = 0.048), but not 100 in the young subjects (r = −0.15, P = 0.43). 101
Intranasal insulin dampens early-sleep cortisol concentrations in elderly subjects 102
Blood parameters did not differ between conditions during baseline (all P ≥ 0.15). In the elderly 103 subjects, insulin compared to placebo administration decreased cortisol concentrations during the first 104 night half (2300-0320 h; F (1,10) = 5.83, P = 0.036 for treatment; t (13) = 2.40, P = 0.03 for the difference 105
in AUC 2300-0020 h ), whereas this effect was absent in young participants (all P > 0.44; F (22, 129) = 2.23, 106 P = 0.003 for treatment × time × age; Figure 1A ). In the elderly, the insulin-induced decrease in 107 cortisol concentrations emerged irrespective of the subjects' sex (P > 0.32). Its extent was proportional 108 to the respective cortisol nadir level in the placebo condition (r = 0.60, P = 0.03, Pearson's 109 coefficient), but was statistically unrelated to changes in nocturnal levels of insulin, C-peptide, and 110 glucose (all P > 0.38; P > 0.46 for the group of young subjects). Plasma ACTH levels were 111 comparable between groups (P = 0.13) and were not influenced by treatment (both P ≥ 0.56 for 112 treatment; all P ≥ 0.10 for single time point comparisons; Figure 1B) . 113
Serum insulin and blood glucose concentrations 114
Serum insulin concentrations were not affected by insulin administration in the elderly subjects (all 115 P ≥ 0.58). In the young participants they rose shortly after substance administration but were 116 comparable between conditions thereafter (P ≥ 0.73 for treatment × time; Figure 1C , upper lines), with 117 no statistical differences to the group of elderly subjects (P = 0.24 for age). In both groups, serum C-118 peptide concentrations slightly decreased after intranasal insulin administration (both P < 0.1 for 119 differences at 2320 h), but did not differ between conditions thereafter (P = 0.68 and P = 0.85, 120 respectively, for treatment × time; P > 0.62 for age). In accordance with the ephemeral increase in 121 peripheral insulin concentrations, in the group of young subjects blood glucose levels were acutely 122 decreased after peptide administration at 2300 h, but subsequently returned to placebo condition 123 values (P = 0.65 for treatment × time). Across conditions, blood glucose levels were lower in elderly 124 than young individuals (P < 0.001 for age; Figure 1C , lower lines).
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Sleep parameters and control measures 126
Independent of the treatment, elderly in comparison to younger subjects had longer wake and light 127 sleep (N1) periods at the expense of slow wave (N3) and REM sleep (F (2,92) = 29.78, P < 0.001 for 128 sleep stage × age group; Table S1 ) assessed across the whole night. Sleepiness ratings and subjective 129 estimations of sleep onset and sleep quality did not differ between groups (all P ≥ 0.20). Intranasal 130 insulin compared to placebo generally did not alter sleep latency, whole-night sleep architecture and 131 total sleep time (all P > 0.29). Early sleep (2300 h-0320 h) likewise was unaffected by insulin in the 132 elderly (all P > 0.13) and young subjects (P > 0.20), as was subjective sleep quality (P > 0.53; Table  133 S1). Self-rated mood as well as hunger, thirst, and sleepiness ratings were not affected by insulin (all 134 P ≥ 0.15; see Table S1 for these and cardiovascular measures). Elderly compared to young subjects 135 showed a trend towards elevated systolic blood pressure values (P = 0.07 for age). Heart rate and 136 blood pressure were generally not modulated by intranasal insulin (all P ≥ 0.18). 137
Discussion 138
We demonstrate that intranasal insulin, which has been shown to reach the brain compartment (Born et humans (Hallschmid et al., 2008) . 158
Intranasal insulin delivery reduced early-sleep cortisol concentrations in elderly but not in 159 young participants. Importantly, sleepiness and subjectively experienced sleep onset and quality were 160 comparable between groups, ruling out acute differences in psychological stress levels as mediators of 161 the observed age-specific insulin effect. It is also unlikely that the small amount of intranasal insulin 162 reaching the blood stream via spillover and causing a short drop in plasma glucose levels masked a 163 centrally inhibiting insulin effect in the younger subjects by stimulating cortisol release. Spillover-164 induced increases in circulating insulin concentrations are negligible (Ott et al., 2015) compared to 165 elevations needed to stimulate HPA axis activity under euglycemic conditions (Fruehwald-Schultes et 166 al., 1999). Moreover, blood glucose levels remained clearly above the hypoglycemic threshold of 3.6-167 3.8 mmol/l where hormonal counterregulation sets in. The fact that changes in cortisol were generally 168 unrelated to parameters of peripheral glucose homeostasis points to a central nervous mediation of 169 insulin's suppressive effect on sleep-related cortisol concentrations in elderly subjects. We were not 170 able to detect treatment effects on ACTH concentrations in the present study, so that an ACTH-171 independent mechanism of adrenal regulation may also be involved (Bornstein et al., 2008) . This 172 question clearly is in need of further clarification. 173
Our finding of an insulin effect in the elderly but not young subjects fits with previous studies 174 indicating that in young, healthy men, attenuating effects of intranasal insulin on basal HPA axis 175 activity only emerge after long-term administration (Benedict et al., 2004) . Acutely attenuating effects 176 of intranasal insulin on basal cortisol concentrations during wakefulness were found in obese 177 (Hallschmid et al., 2008) , but not in normal-weight men (Benedict et al., 2004) . Obesity is associated 178
with and also appears to be promoted by excessive HPA axis secretion, e.g., due to chronic stress 179 . In our sample of elderly subjects, BMI was positively related to serum cortisol concentrations 182 during the first night-half. In general, however, the elderly participants of the present study displayed a 183 high level of physical health and only moderate signs of nocturnal HPA axis up-regulation, which 184 might explain the relative subtlety of the observed insulin effect. Still, the extent of insulin-induced 185 cortisol reductions was associated with the height of respective cortisol nadir levels. Therefore, 186 inhibitory effects of insulin on HPA axis secretory activity are expected to be stronger in aging 187 subjects who show weaker nocturnal stress axis inhibition. In these subjects, intranasal insulin may be 188 a helpful means to normalize nocturnal HPA axis activity and improve sleep-associated endocrine 
